Compare VIPS & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIPS | AMRX |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.8B |
| IPO Year | 2012 | 2018 |
| Metric | VIPS | AMRX |
|---|---|---|
| Price | $15.25 | $18.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $19.58 | $15.60 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 05-19-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.38% | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | N/A |
| Revenue This Year | $3.79 | $4.48 |
| Revenue Next Year | $2.05 | $7.13 |
| P/E Ratio | ★ $9.00 | $96.87 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.65 | $7.80 |
| 52 Week High | $21.08 | $19.26 |
| Indicator | VIPS | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.23 | 57.29 |
| Support Level | $14.78 | $12.46 |
| Resistance Level | $15.87 | $18.13 |
| Average True Range (ATR) | 0.37 | 0.60 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 98.05 | 54.10 |
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.